Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells

Allogeneic cardiac-derived progenitor cells (CPC) without immunosuppression could provide an effective ancillary therapy to improve cardiac function in reperfused myocardial infarction. We set out to perform a comprehensive preclinical feasibility and safety evaluation of porcine CPC (pCPC) in the infarcted porcine model, analyzing biodistribution and mid-term efficacy, as well as safety in healthy non-infarcted swine.This work was mainly supported by the European FP7-HEALTH-2009-1.4-3, Grant Agreement 242038. In addition, it was partially supported by FEDER funds and grants from the Ministerio de Economia industria y Competitividad ISCIII (PI16/01172) co-funded by ERDF/ESF, “Investing in your future” and Junta de Extremadura Consejeria de Economía e Infraestructuras (IB16201) to VC, and the Spanish Ministry of Science and Innovation (SAF2015-70882-R; AEI/FEDER, UE) and the Instituto de Salud Carlos III (RETICS-RD12/0019/0018) to AB.Peer reviewe